Table 2.
Crude and adjusted odds ratios (ORs) of Parkinsonism associated with the use of metoclopramide.
| Case | Control | Crude | Adjusteda | |
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||
| Metoclopramide use | ||||
| Never | 256 (47.3) | 2,811 (55.3) | 1.00 | 1.00 |
| Ever | 285 (52.7) | 2,274 (44.7) | 1.40 (1.17–1.68) | 1.39 (1.16–1.67) |
| Duration between first and last prescriptionb | ||||
| No | 256 (47.3) | 2,811 (55.3) | 1.00 | 1.00 |
| 1–28 | 84 (15.5) | 797 (15.7) | 1.19 (0.91–1.54) | 1.18 (0.91–1.54) |
| 29–677 | 91 (16.8) | 705 (13.9) | 1.43 (1.11–1.84) | 1.42 (1.10–1.83) |
| >677 | 110 (20.3) | 772 (15.2) | 1.63 (1.27–2.11) | 1.63 (1.26–2.10) |
| p for trend | <0.001 | |||
| Cumulative duration of use (days)b | ||||
| No | 256 (47.3) | 2,811 (55.3) | 1.00 | 1.00 |
| 1–8 | 77 (14.2) | 812 (16.0) | 1.06 (0.81–1.39) | 1.06 (0.81–1.39) |
| 9–41 | 82 (15.2) | 696 (13.7) | 1.32 (1.02–1.73) | 1.31 (1.00–1.71) |
| >41 | 126 (23.3) | 766 (15.1) | 1.88 (1.48–2.38) | 1.87 (1.47–2.37) |
| p for trend | <0.001 | |||
| Cumulative dose of metoclopramideb | ||||
| No | 256 (47.3) | 2,811 (55.3) | 1.00 | 1.00 |
| 1–103 mg | 76 (14.1) | 766 (15.1) | 1.11 (0.84–1.45) | 1.10 (0.84–1.45) |
| 104–449 mg | 79 (14.6) | 735 (14.5) | 1.21 (0.92–1.58) | 1.20 (0.92–1.57) |
| >449 mg | 130 (24.0) | 773 (15.2) | 1.92 (1.52–2.43) | 1.91 (1.51–2.42) |
| p for trend | <0.001 | |||
a
Each model adjusted for sex, age, duration from diabetes to index date, hypertension, hyperlipidemia, ever use of statin, and antipsychotics.
b
Categories based on the distribution of metoclopramide use of control group.
CI, confidence interval.